Pancreatic Cancer Research

GrantZIANCI Division of Basic Sciences (intramural)

The Role of Protein Methylation in Squamous Cell Carcinoma of the Head and Neck

Activity
ZIA
Institute
NCI Division of Basic Sciences (intramural)
Fiscal years counted
2024
Amount counted
$1,300,908

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Abstract public domain (NIH RePORTER)

Head and neck squamous cell carcinoma (HNSCC) is the sixth most prevalent non-skin cancer in the world, causing 890,000 new cases and 450,000 deaths in 2018. HNSCC is categorized into two main pathogenetic types: human-papilloma-virus (HPV)-positive and HPV-negative, which has strong associations with tobacco use. HPV-negative HNSCC is associated with a worse prognosis and treatment is often multimodal and toxic, with the use of surgical intervention, platinum-based chemotherapy and radiation therapy. Despite this intense multimodality therapy, approximately 50% of patients with HPV-negative HNSCC recur either locoregionally or with distant metastases. Even with the advent of immunotherapy, patients with recurrent/metastatic disease have a dismal prognosis, with a median overall survival of approximately 13 months. Based on the above, novel therapeutic approaches are urgently needed. SET and MYND-domain containing protein 3 (SMYD3) is a protein lysine methyltransferase with oncogenic activity in multiple cancer types, such as colon, hepatocellular carcinoma, lung and pancreatic cancer. It methylates histone substrates, such as H3K4me3, enabling its function as a chromatin modifier, as well as non-histone substrates, such as MAP3K2, VEGFR1 and HER2, which mediates its cytoplasmic functions [Hamamoto et al, Nat.Rev.Cancer, 2016]. Over the past 2 years, our lab has focused on the function of SMYD3 as an oncogenic chromatin modifier and novel therapeutic target in HPV-negative HNSCC. We have found that SMYD3 is significantly overexpressed in ~60% of HPV-negative HNSCC tumors [Nigam et al, Cell Rep. 2023], and that SMYD3 depletion significantly decreases the proliferative and colony forming capacity, cell cycling and the invasive potential of HPV-negative HNSCC cell lines, while it also significantly reduces tumor growth in immunocompromised mouse models of flank tumor xenografts [Murali et al, 2024, under review, Sci. Rep.]. Our findings support that these phenotypes are mediated through a bifaceted transcription function, whereby SMYD3 binds to and acts as an activator or repressor of specific cell cycle and epithelial-mesenchymal transition genesets within the same cell context [Murali et al, 2024, under review, Sci. Rep]. Furthermore, we have reported that Smyd3 depletion using anti-sense oligonucleotides (ASOs), which degrade Smyd3 mRNA, sensitizes HPV-negative MOC1 flank mouse tumors to anti-PD-1 therapy by increasing the intratumoral influx of CD8+ T-cells, reinvigorating exhausted CD8+ T-cells and upregulating the protein levels of PD-1 on CD8+ T-cells, and H2-Kb on MOC1 cells in vivo. Combined Smyd3 depletion and anti-PD-1 therapy enhances IFN response signatures in MOC1 tumors and leads to cure of 50% of MOC1 tumors and significant shrinkage in 25% of the treated tumors [Tsai et al, 2024, iScience, Nigam et al, Cell Rep. 2023]. Mechanistically, we reported that loss of SMYD3 increases the sensitivity of HPV-negative HNSCC cancer cells to interferon-b (IFN-b) and induces transcriptional upregulation of multiple type I IFN response genes through the regulation of UHRF1, a major epigenetic H3K9me3 reader which binds on the promoters of key immune-related genes and recruits DNMT1, and through the deposition of the repressive mark H4K20me3 on the gene bodies of immune-related genes in human HPV-negative HNSCC cells [Nigam et al, Cell Rep. 2023]. Further, we found that SMYD3 overexpression is associated with decreased tumor CD8+ T-cell infiltration and poor response to neoadjuvant pembrolizumab in patients with HPV-negative HNSCC. Building upon the aforementioned findings, the goal of this research program over the upcoming 4 years is to elucidate the specific mechanisms through which SMYD3 exerts its bifaceted transcriptional effect in the nucleus of HPV-negative HNSCC cells, determine the cytoplasmic functions of SMYD3 in HPV-negative HNSCC, and to develop PROteolysis-Targeting Chimeras (PROTACs) targeting SMYD3.

Abstract public domain (NIH RePORTER)

To this purpose, the following aims will be pursued: Specific Aim 1: Determine the epigenetic mechanisms through which SMYD3 exerts a bifaceted repressive and activating transcriptional effect in HPV-negative HNSCC. Hypothesis: SMYD3 mediates the formation of specific transcriptional complexes that enable its function as a repressor and activator in HPV-negative HNSCC cells. We have found that SMYD3 promotes the deposition of H4K20me3 on the gene bodies of immune-related genes, inducing their repression. We will conduct immunoprecipitation of the SMYD3 chromatin-bound fraction from nuclear extracts of HPV-negative HNSCC cells (HN-6 cell line), and then mass spectrometry analysis to identify interacting proteins of SMYD3 in its chromatin-bound form. The top 5 significant interacting candidate partners will be sorted and validated with co-immunoprecipitation in two cell lines. CUTandRUN assays of the validated partners will be conducted to confirm chromatin binding and evaluate co-occupancy patterns with SMYD3. Transient knockdown of each of these candidates will be conducted using siRNAs to assess their activating or repressive effect on transcription. CUTandRUN assays for repressive histone marks (H4K20me3, H3K27me3, H3K9me3) will also be pursued to assess whether SMYD3 affects the deposition of these histone marks. Specific Aim 2: Determine and dissect the functions of non-histone cytoplasmic substrate(s) of SMYD3 in HPV-negative HNSCC. Hypothesis: SMYD3 mediates oncogenic effects through a non-histone cytoplasmic substrate(s) in HPV-negative HNSCC. The SILAC method will be utilized to identify candidate non-histone cytoplasmic substrates of SMYD3 in HPV-negative HNSCC cells (HN-6 cell line). Using the top 5 candidate methylation substrates, in vitro methyltransferase assays will be conducted with recombinant proteins/peptides using tritium-labeled SAM, followed by mass spectrometry to identify the specific methylation site. A customized antibody will then be generated to further validate the induction of the specific methylation in cancer cells. Based on the known function of the specific substrate, loss- and gain-of-function experiments will be designed with the methylation-mutant substrate and enzymatically active or inactive SMYD3 CRISPR expressing cell lines to dissect the function of the methylated substrate in HPV-negative HNSCC cells. Specific Aim 3: Develop PROteolysis-Targeting Chimeras (PROTACs) targeting SMYD3. Hypothesis: SMYD3 targeting PROTACs are effective in degrading SMYD3 protein levels and are more efficacious than available SMYD3 enzymatic inhibitors in suppressing the oncogenic phenotypes of HPV-negative HNSCC cells in vitro and in vivo. Ten SMYD3 PROTAC lead compounds have already been generated and have manifested significant antiproliferative activity in multiple HPV-negative HNSCC cell lines. In vivo toxicity experiments, pharmacokinetic (PK) and efficacy studies using SCID mice will be conducted to identify compounds with the most favorable toxicity, PK and PD profile. These compounds will be further compared with the available SMYD3 enzymatic inhibitors to assess their effect on SMYD3-induced epigenetic and non-epigenetic pathways. An enzymatically-dead SMYD3 expressing cell line will be generated using CRISPR knock-in and its proliferative and colony-forming capacity, invasive capacity and type I IFN-responsiveness will be compared with that of an already available SMYD3 KO and a control wild type cell line.